Abstract
Background: Cost-effectiveness of calcium supplementation depends not only on the cost of the product but on the efficiency of its absorption. Published cost-benefit analyses assume equal bioavailability for all calcium sources. Some published studies have suggested that there are differences in both the bioavailability and cost of the major calcium supplements. Design: Randomized four period, three-way cross-over comparing single doses of off-the-shelf commercial calcium supplements containing either calcium carbonate or calcium citrate compared with a no-load blank and with encapsulated calcium carbonate devoid of other ingredients; subjects rendered fully vitamin D-replete with 10 μg/day 25(OH)D by mouth, starting one week prior to the first test. Subjects: 24 postmenopausal women Methods: Pharmacokinetic analysis of the increment in serum total and ionized calcium and the decrement in serum iPTH induced by an oral calcium load, based upon multiple blood samples over a 24-hour period; measurement of the rise in urine calcium excretion. Data analyzed by repeated measures ANOVA. Cost calculations based on average retail prices of marketed products used in this study from April through October, 2000. Results: All three calcium sources (marketed calcium carbonate, encapsulated calcium carbonate and marketed calcium citrate) produced identical 24-hour time courses for the increment in total serum calcium. Thus, these were equally absorbed and had equivalent bioavailability. Urine calcium rose slightly more with the citrate than with the carbonate preparations, but the difference was not significant. Serum iPTH showed the expected depression accompanying the rise in serum calcium, and there were no significant differences between products. Conclusion: Given the equivalent bioavailability of the two marketed products, the cost benefit analysis favors the less expensive carbonate product.
| Original language | English |
|---|---|
| Pages (from-to) | 239-246 |
| Number of pages | 8 |
| Journal | Journal of the American College of Nutrition |
| Volume | 20 |
| Issue number | 3 |
| State | Published - 2001 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine (miscellaneous)
- Food Science
Cite this
Absorbability and cost effectiveness in calcium supplementation. / Heaney, R. P.; Dowell, M. S.; Bierman, J.; Hale, C. A.; Bendich, A.
In: Journal of the American College of Nutrition, Vol. 20, No. 3, 2001, p. 239-246.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Absorbability and cost effectiveness in calcium supplementation
AU - Heaney, R. P.
AU - Dowell, M. S.
AU - Bierman, J.
AU - Hale, C. A.
AU - Bendich, A.
PY - 2001
Y1 - 2001
N2 - Background: Cost-effectiveness of calcium supplementation depends not only on the cost of the product but on the efficiency of its absorption. Published cost-benefit analyses assume equal bioavailability for all calcium sources. Some published studies have suggested that there are differences in both the bioavailability and cost of the major calcium supplements. Design: Randomized four period, three-way cross-over comparing single doses of off-the-shelf commercial calcium supplements containing either calcium carbonate or calcium citrate compared with a no-load blank and with encapsulated calcium carbonate devoid of other ingredients; subjects rendered fully vitamin D-replete with 10 μg/day 25(OH)D by mouth, starting one week prior to the first test. Subjects: 24 postmenopausal women Methods: Pharmacokinetic analysis of the increment in serum total and ionized calcium and the decrement in serum iPTH induced by an oral calcium load, based upon multiple blood samples over a 24-hour period; measurement of the rise in urine calcium excretion. Data analyzed by repeated measures ANOVA. Cost calculations based on average retail prices of marketed products used in this study from April through October, 2000. Results: All three calcium sources (marketed calcium carbonate, encapsulated calcium carbonate and marketed calcium citrate) produced identical 24-hour time courses for the increment in total serum calcium. Thus, these were equally absorbed and had equivalent bioavailability. Urine calcium rose slightly more with the citrate than with the carbonate preparations, but the difference was not significant. Serum iPTH showed the expected depression accompanying the rise in serum calcium, and there were no significant differences between products. Conclusion: Given the equivalent bioavailability of the two marketed products, the cost benefit analysis favors the less expensive carbonate product.
AB - Background: Cost-effectiveness of calcium supplementation depends not only on the cost of the product but on the efficiency of its absorption. Published cost-benefit analyses assume equal bioavailability for all calcium sources. Some published studies have suggested that there are differences in both the bioavailability and cost of the major calcium supplements. Design: Randomized four period, three-way cross-over comparing single doses of off-the-shelf commercial calcium supplements containing either calcium carbonate or calcium citrate compared with a no-load blank and with encapsulated calcium carbonate devoid of other ingredients; subjects rendered fully vitamin D-replete with 10 μg/day 25(OH)D by mouth, starting one week prior to the first test. Subjects: 24 postmenopausal women Methods: Pharmacokinetic analysis of the increment in serum total and ionized calcium and the decrement in serum iPTH induced by an oral calcium load, based upon multiple blood samples over a 24-hour period; measurement of the rise in urine calcium excretion. Data analyzed by repeated measures ANOVA. Cost calculations based on average retail prices of marketed products used in this study from April through October, 2000. Results: All three calcium sources (marketed calcium carbonate, encapsulated calcium carbonate and marketed calcium citrate) produced identical 24-hour time courses for the increment in total serum calcium. Thus, these were equally absorbed and had equivalent bioavailability. Urine calcium rose slightly more with the citrate than with the carbonate preparations, but the difference was not significant. Serum iPTH showed the expected depression accompanying the rise in serum calcium, and there were no significant differences between products. Conclusion: Given the equivalent bioavailability of the two marketed products, the cost benefit analysis favors the less expensive carbonate product.
UR - http://www.scopus.com/inward/record.url?scp=0034954644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034954644&partnerID=8YFLogxK
M3 - Article
VL - 20
SP - 239
EP - 246
JO - Journal of the American College of Nutrition
JF - Journal of the American College of Nutrition
SN - 0731-5724
IS - 3
ER -